Amgen (AMGN) Announces Study Results on Parsabiv in sHPT Published in JAMA Jan 10, 2017 04:20PM
Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv™ (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparath Jan 10, 2017 04:12PM
Amgen (AMGN) Enters New Six-Year Sourcing and Supply Agreement with DaVita (DVA) Jan 9, 2017 06:21AM
Amgen And DaVita Enter Into New Sourcing And Supply Agreement Jan 9, 2017 06:00AM
Amgen (AMGN), Immatics Biotechnologics To Collaborate On Novel Bispecific Cancer Immunotherapies Development Jan 9, 2017 04:02AM
View Older Stories

Jan 9, 2017 04:00AM Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Jan 6, 2017 01:19AM Amgen (AMGN) Request For Permanent Injunction For Repatha Patent Infringement By Sanofi & Regeneron Granted By US Court
Jan 5, 2017 09:34PM Court Grants Permanent Injunction For Infringement Of Amgen's Repatha Patents
Jan 4, 2017 04:00PM Amgen To Present At The 35th Annual J.P. Morgan Healthcare Conference
Dec 20, 2016 04:20PM Amgen Announces 15 Percent Increase In 2017 First Quarter Dividend
Dec 19, 2016 07:00PM Amgen And UCB Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan
Dec 16, 2016 09:10AM Amgen (AMGN) Receives Positive CHMP Opinion on New Repatha Dose Delivery Option
Dec 16, 2016 09:00AM New Repatha® (evolocumab) Dose Delivery Option Receives Positive CHMP Opinion
Dec 2, 2016 04:00PM Amgen Announces Launch Of Blood Counts™ And Collaboration With StoryCorps To Record And Share Stories Of Those Impacted By Multiple Myeloma
Dec 2, 2016 09:01AM Amgen (AMGN), Allergan (AGN) Announce Submission of ABP 215 MAA to EMA
Dec 2, 2016 09:00AM Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab
Dec 1, 2016 04:00PM Amgen To Present At The Citi 2016 Global Healthcare Conference
Dec 1, 2016 06:36AM Amgen (AMGN), Cytokinetics (CYTK) Announce Publication of Significant Omecamtiv Mecarbil Phase 2 Data
Nov 30, 2016 06:31PM The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure
Nov 30, 2016 06:30PM The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function in Patients With Chronic Heart Failure
Nov 30, 2016 10:00AM Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Multiple Myeloma And Immune Thrombocytopenia At ASH 2016
Nov 21, 2016 11:34AM Arrowhead Research (ARWR) Reports Closing of License and Collaboration Agreement with Amgen (AMGN) on RNAi ARC-LPA Program
Nov 16, 2016 04:30PM Amgen (AMGN) Announces Erenumab Phase 3 Met Primary Endpoint as Migraine Treatment
Nov 16, 2016 04:30PM Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In Second Phase 3 Study
Nov 15, 2016 04:01PM Amgen (AMGN) , Allergan (AGN) Submit Biosimilar BLA for ABP 215
Nov 15, 2016 04:00PM Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration
Nov 15, 2016 12:46PM Amgen (AMGN) Announces Significant Data for Repatha in Regressing CAD-Related Atherosclerosis
Nov 15, 2016 12:28PM Repatha® (Evolocumab) Regresses Atherosclerosis In Patients With Coronary Artery Disease
Nov 14, 2016 09:00AM New 'Ten To Watch' List Highlights Top Amgen Scholars Poised To Impact The Future Of Science And Medicine
Nov 14, 2016 06:55AM Amgen (AMGN), UCB Announce Significant Data from Phase 3 BRIDGE Study for Increasing BMD in Men With Osteoporosis
Nov 12, 2016 04:30PM Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis
Nov 11, 2016 04:01PM Amgen (AMGN) Reports EC Approval for Parsabiv to Treat sHPT in Adults with CKD
Nov 11, 2016 04:00PM European Commission Approves Parsabiv™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis
Nov 10, 2016 04:00PM Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2016
Nov 10, 2016 08:35AM Amgen (AMGN) Enters Multiple Myeloma Collaboration with Janssen
Nov 10, 2016 08:33AM Amgen Announces Collaboration With Janssen To Co-Fund Studies With KYPROLIS® (Carfilzomib) And DARZALEX® (Daratumumab) In Patients With Multiple Myeloma
Nov 7, 2016 04:00PM Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's Ongoing Commitment To Therapies For Patients With Serious Inflammatory And Bone Diseases
Nov 7, 2016 07:30AM Amgen (AMGN) Receives FDA Approval for ENBREL sBLA as Expanded Indication
Nov 4, 2016 05:26PM FDA Approves Expanded Use Of ENBREL® (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis
Nov 3, 2016 04:01PM Amgen To Present At The Credit Suisse 25th Annual Healthcare Conference
Nov 2, 2016 09:00AM Amgen Appoints Lori Johnston As Senior Vice President, Human Resources
Oct 31, 2016 04:17PM Amgen Highlights Repatha® (Evolocumab) GLAGOV Imaging Study Amongst Data To Be Presented At AHA Scientific Sessions 2016
Oct 27, 2016 04:01PM Amgen Reports Third Quarter 2016 Financial Results
Oct 26, 2016 02:46PM Trading Radar for 10/27: Alphabet (GOOG), Amazon (AMZN), Twitter (TWTR) Ford (F), (BIDU) Report
Oct 25, 2016 05:43AM Amgen (AMGN) Makes Investment in Israel-Based eHealth Ventures
Oct 25, 2016 05:30AM Amgen To Invest In Israel-Based eHealth Ventures
Oct 24, 2016 04:00PM Amgen Announces Webcast Of 2016 Third Quarter Financial Results
Oct 20, 2016 04:20PM Amgen (AMGN) Announces XGEVA vs. Zoledronic Acid Study Met Primary Endpoint; Secondary Endpoints Missed
Oct 20, 2016 04:19PM Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients
Oct 14, 2016 04:05PM Amgen Announces 2016 Fourth Quarter Dividend
Oct 14, 2016 04:01PM Amgen (AMGN) Adds Former DuPont CEO Kullman as Director
Oct 14, 2016 04:00PM Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors
Oct 10, 2016 09:11AM Amgen (AMGN) Announces Additional Data from Vectibix in mCRC; Increased OS Observed
Oct 10, 2016 09:09AM New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Le
Oct 5, 2016 04:10PM Amgen (AMGN) Plans Presentation of New IMLYGIC Combo Data in Metastatic Colorectal Cancer at ESMO 2016
View Older Stories